Thalidomide was initially synthesised in 1954 and marketed as a sedative and antiemetic for morning sickness. It was withdrawn in 1961 due to the realisation that it was teratogenic with over 10 000 children born with congenital abnormalities. Since then it has been used for treatment of dermatological and oncological conditions, including myeloma. In 1994, it was found to have a potent antiangiogenic effect via downregulation of vascular endothelial growth factor (VEGF). This has led to its use in gastrointestinal bleeding, as vascular abnormalities such as angiodysplasia have been found to have elevated VEGF levels. This article will review the current evidence of the use of thalidomide in bleeding associated with gastrointestinal vascular malformations, including angiodysplasia, gastric cancer and radiation-induced proctitis.
(p<0.001), investigation 3.02±0.72 to 3.47±0.64 (p<0.001), management 3.25±0.72 to 3.52±0.61 (p=0.016), recognition of dermatological lesions 3.07±0.74 to 3.97±0.55 (p<0.001), description of describing dermatological lesions 2.98±0.86 to 3.82±0.58 (p<0.001). Students agreed that gameplay was interactive (100%), motivational (97%), achieved learning goals (80%), identified weaknesses (88%), incorporated sufficient feedback (91%), facilitated learning through teamwork (91%) and was less stressful than traditional methods of teaching (86%). Qualitative themes included group participation, variation of topics and learning styles, knowledge application and enjoyment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.